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Regulation of lung immunity and host
defense by the intestinal microbiota
Derrick R. Samuelson, David A. Welsh and Judd E. Shellito *
Section of Pulmonary/Critical Care and Allergy/Immunology, Department of Medicine, Louisiana State University Health
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Every year in the United States approximately 200,000 people die from pulmonary
infections, such as influenza and pneumonia, or from lung disease that is exacerbated by
pulmonary infection. In addition, respiratory diseases such as, asthma, affect 300 million
people worldwide. Therefore, understanding the mechanistic basis for host defense
against infection and regulation of immune processes involved in asthma are crucial for
the development of novel therapeutic strategies. The identification, characterization, and
manipulation of immune regulatory networks in the lung represents one of the biggest
challenges in treatment of lung associated disease. Recent evidence suggests that the
gastrointestinal (GI) microbiota plays a key role in immune adaptation and initiation in the
GI tract as well as at other distal mucosal sites, such as the lung. This review explores the
current research describing the role of the GI microbiota in the regulation of pulmonary
immune responses. Specific focus is given to understanding how intestinal “dysbiosis”
affects lung health.
Keywords: Gut-Lung Axis, intestinal microbiota, immunology, pulmonary infections, pulmonary immunology,
dysbiosis
Introduction
Respiratory tract infectious diseases, such as influenza and pneumonia, result in the death of
3·2 million people annually worldwide (WHO, 2014). Most of the current therapies used in the
treatment and management of these diseases are suboptimal as antibiotic resistance, efficacy, and
toxicity have been difficult to overcome (Keely et al., 2011). Infection of the respiratory tract
represents a breakdown of the host’s immune defenses. In addition, non-infections respiratory
diseases are the third and fifth (infections respiratory diseases are the fourth) leading causes of death
worldwide (WHO, 2014). Understanding the mechanisms that mediate cross-talk between the
gastrointestinal (GI) tract and lung defenses and how this interaction facilitates optimal lung health
is of growing interest. More specifically, the role of the GI microbiota in mediating, maintaining,
and regulating this cross-talk represents an exciting area of research that is poised to aid in the
development of novel treatment and management strategies for lung disease.
The Human “Super-Organism”: The Role of the Gastrointestinal
Microbiota in Health
The importance of the homeostatic maintenance of human health by the intestinal microbiota
has become a topic of great interest (Noverr and Huffnagle, 2004; Lupp et al., 2007;
Maslowski et al., 2009; Garrett et al., 2010; Hooper et al., 2012; Bollrath and Powrie, 2013;
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Sansonetti, 2013). Evolution of an individual’s microbiota begins
shortly after birth cumulating in a stable adult microbiota by
the age of two (Foxx-Orenstein and Chey, 2012). This microbial
community includes autochthonous (permanent inhabitants)
and allochthonous (transient inhabitants) microorganisms.
Microbiota of the humanGI tract contains bacterial (microbiota),
viral (virome), and fungal (mycobiota) species. Surprisingly,
approximately 60% of these organisms cannot be grown in
traditional culture (Noverr and Huffnagle, 2004; Hooper et al.,
2012). However, newmethods known as “microbial culturomics,”
which utilize 212 different culture conditions have allowed for
a significant advancement in our ability to culture intestinal
microorganisms (Lagier et al., 2012). The average human
adult intestinal microbiota is composed of approximately 400–
1000 species (Noverr and Huffnagle, 2004; McLoughlin and
Mills, 2011; Hooper et al., 2012). However, it is estimated
that roughly 30-40 species dominate this niche, with bacteria
from the genera Bacteroides, Bifidobacterium, Eubacterium,
Fusobacterium, Clostridium, and Lactobacillus highly represented
(McLoughlin and Mills, 2011). In addition, intestinal microbial
diversity and composition changes not only along the length of
the intestinal tract but is spatially distributed between the mucosa
and the lumen of the intestinal tract within each region (Hill
et al., 2010;Macpherson andMcCoy, 2013). Many environmental
factors will drastically alter the normal intestinal microbiota
(Noverr and Huffnagle, 2004). Changes in diet, the use of
antibiotics, chemotherapy, GI tract infection, and host immune
status significantly alter, either transiently or permanently, the
intestinal ecosystem (Round and Mazmanian, 2009; Hooper
and Macpherson, 2010; Hooper et al., 2012). Alterations of
the microbiota that lead to intestinal dysbiosis (a microbial
imbalance within the intestinal tract) are characterized by a
loss or significant decrease in the amount of beneficial bacterial
species and/or an outgrowth or population shift of other species.
Intestinal dysbiosis can affect overall health in multiple ways
such as growth of opportunistic bacterial pathogens, alterations
in host’s metabolic profiles, and/or increased inflammation. This
review will focus on the microbiota as it affects pulmonary
immunity.
Maintenance of the Intestinal Microbiota
Alterations of the intestinal microbiota not only affect the growth
of opportunistic pathogens but can have a broad impact on
immune status and function within the host (Hooper et al., 2012).
The impact of the GI microbiota on host mucosal immunity
has been studied extensively in germ-free mice (mice without
any intestinal microbiota). Germ-free mice exhibit impaired
GI development characterized by smaller Peyer’s patches, fewer
CD8αβ intraepithelial lymphocytes, underdeveloped isolated
lymphoid follicles, and lower levels of the mucosal IgA antibodies
(Hooper et al., 2012). The specific microbial molecules or
components that inform host immune development are still
being discovered and characterized. These interactions are
crucial for the maintenance of host-microbial homeostasis. This
topic has been reviewed in several recent articles (Round and
Mazmanian, 2009; Hooper and Macpherson, 2010; Hooper et al.,
2012). Figure 1 highlights a current overview of understanding
of how the GI microbiota shape immune responses and how the
host immune system shapes the GI microbiota.
The Intestinal Microbiota and Systemic
Immunity
Commensal microorganisms modulate host immunity not only
in the intestinal tract but at distal sites as well (Kieper et al., 2005).
The intestinal microbiota affects systemic immune responses by
modulation of several key pathways; expansion of extra-intestinal
T cell populations, production of short-chain fatty acids,
development of oral tolerance, and control of inflammation.
Regulation of T Cell Populations
Expansion and differentiation of extra-intestinal T cell
populations are meditated by the intestinal microbiota (Kieper
et al., 2005). Several recent studies have shown that the intestinal
microbiota is critical for maintenance of T cell subsets that are
important for systemic immunity. The intestinal microbiota is
required for expansion of CD4+ T cells, regulatory T cells, Th1
or Th2 responses, and Th17 T cells. For example, colonization
of germ-free mice with Bacteroides fragilis that synthesize PSA
results in a higher number of circulating CD4+ T cells and
levels of circulating Th1 cells compared to mice colonized with
B. fragilis unable to produce PSA (Mazmanian et al., 2005).
While, colonization of gnotobiotic mice with a cocktail of mouse
derived Clostridial strains enhances anti-inflammatory signaling
by directing the expansion of lamina propria and systemic
regulatory T cells (Treg) with an associated increase in IL-10
secretion (Atarashi et al., 2011). The specific Clostridial strain
that drives this regulatory affect is not known. Further, mice with
high levels of Bacteroides vulgatus colonization exhibit a biased
T cell differentiation favoring a Th2 over a Th1 phenotype, as
characterized by increased levels of IgE, IgG1, IL-4 and decreased
IFNγ (Sudo et al., 2002) Finally, colonization of germ-free mice
with segmented filamentous bacteria (SFB) induces expansion
of the Th17 cell population and a slight increase in Th1 cells
(Abraham and Cho, 2009; Wu et al., 2010; Lee et al., 2011).
Oral Tolerance
Development of oral tolerance occurs following oral
administration of antigen and represents a local and systemic
immunological state of immune unresponsiveness to a
subsequent antigen challenge. Low doses of antigen favor
active suppression, whereas higher doses favor clonal deletion
of antigen-specific T cells. Ingestion of oral antigen induces
expansion of Th2 and Th3 T cells and CD4+ CD25+ regulatory
cells and latency-associated peptide+ T cells (Faria and Weiner,
2005). Further, individuals with impaired intestinal permeability
often have dysfunctional oral tolerance. Impaired intestinal
permeability also leads to inadequate production of IgE and
recruitment of mast cells in the GI mucosa. Individuals suffering
from these conditions exhibit enhanced IgE-CD23-mediated
transport across the mucosa and increased levels of inflammatory
mediators, such as proteases and cytokines, which further affect
intestinal permeability. This leads to an increase in the leakage of
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FIGURE 1 | The intestinal microbiota and the host immune system. Interaction between the immune system and the intestinal microbiota. Multiple immune
effectors function together to minimize bacterial-epithelial invasion. These include the mucus layer, epithelial antibacterial proteins, and IgA secreted by lamina propria
plasma cells. Compartmentalization is accomplished by unique anatomic adaptations that limit commensal bacterial exposure to the immune system. Some microbes
are sampled by intestinal DCs. The loaded DCs traffic to the mesenteric lymph nodes through the intestinal lymphatic but do not migrate to distal tissues. This
compartmentalizes live bacteria and induction of immune responses to the mucosal immune system. Induced B cells and T cell subsets recirculate through the
lymphatic and the bloodstream back to mucosal sites, where B cells differentiate into IgA-secreting plasma cells. Thus, the intestinal microbiota shapes host mucosal
as well as systemic immunity. ILFs, isolated lymphoid follicles.
allergens and hence contributes to perpetuate the inflammatory
reaction (Perrier and Corthésy, 2011). Further, Cassani and
colleagues recently observed defective oral tolerance in CCR9-
deficient mice (CCR9 targets T cells to the small intestine) and
that defective oral tolerance in CCR9-deficieint mice could be
restored by transfer of wild-type T cells (Cassani et al., 2011).
However, Pabst and co-workers found that CCR9-deficient
mice developed normal oral tolerance to ovalbumin. Pabst and
co-workers suggest that these differences may be due to the
differences in individual strains of CCR9-deficient mice, or that
differences in the composition of the microbiota may influence
the impact of CCR9 on oral tolerance (Pabst and Mowat, 2012).
There are controversial reports on the capacity to induce oral
tolerance in germ-free mice devoid of live intestinal bacteria
(Walton et al., 2006; Ishikawa et al., 2008). Yet, numerous studies
have demonstrated that the intestinal microbiota has a profound
effects on the immune system. Therefore, it is conceivable that
differences in microbiota composition may also affect oral
tolerance.
Production of Short-chain Fatty Acids
Dietary fermentable fiber content changes the composition
of the GI microbiota, in particular by altering the ratio of
Firmicutes to Bacteroidetes. Alteration of the ratio of Firmicutes
to Bacteroidetes directly affect how the gut microbiota metabolize
fiber, consequently increasing or decreasing the concentration of
circulating short-chain fatty acids (SCFAs). Intestinalmicrobiota-
meditated production of various SCFAs have also been shown
to be important for host systemic immunity (Meijer et al.,
2010; den Besten et al., 2013; Trompette et al., 2014). More
precisely, SCFAs, especially butyrate, seem to exert broad anti-
inflammatory activities by affecting immune cell migration,
adhesion, cytokine expression, as well as, cellular proliferation,
activation, and apoptosis through the activation of signaling
pathways (NF-κB) and inhibition of histone deacetylase. In
addition, histone deacetylase inhibitors enhance the numbers and
function of Treg cells (Meijer et al., 2010). Two recent studies
demonstrated that short-chain fatty acids directly regulate/prime
the size and function of Treg cell pool in the colon. Both studies
showed that mice are protected from colitis through butyrate
induced differentiation of Treg cells in a Ffar2-dependentmanner
(Furusawa et al., 2013; Smith et al., 2013). Furusawa and colleges
also demonstrated that treatment of naive T cells under the
Treg-cell-polarizing conditions with butyrate enhanced histone
H3 acetylation in the promoter and conserved non-coding
sequence regions of the Foxp3 locus, which they proposed may
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be the possible mechanism for how microbial-derived butyrate
regulates the differentiation of Treg cells (Walton et al., 2006).
Increased levels of butyrate also induce the expression of IL-
10, which influence the balance between Th1, cytotoxic CD8+
T cells and Treg cells. Finally, SCFAs are also important in the
control of allergic inflammation. Trompette and colleagues found
that mice fed a high-fiber diet had increased circulating levels
of SCFAs and were protected against allergic inflammation in
the lung, whereas a low-fiber diet decreased levels of SCFAs
and increased allergic airway disease. Specifically, increased
levels of SFAs lead to enhanced generation of dendritic cell
precursors and subsequent seeding of the lungs by DCs with
high phagocytic capacity, which was accompanied by an impaired
ability to promote Th2 cell effector function (Trompette et al.,
2014).
Regulation of Systemic Inflammation
Several recent studies have provided insight into the role
that the commensal microbiota has on influencing systemic
inflammation (Noverr et al., 2004, 2005; Ichinohe et al., 2011).
Disease severity in animal models of colitis are all dependent
on the animal’s intestinal microbial communities (Abraham and
Cho, 2009; Wu et al., 2010; Lee et al., 2011). For example,
germ-free mice with chemically induced colitis exhibit markedly
attenuated pathological signs of colitis and restoration of the
intestinal microbiota prevents the attenuation. This suggests that
the intestinal microbiota is crucial for modulating the host’s
ability to control inflammation. Further, Verdam et al., found that
obese humans exhibit a reduced bacterial diversity, a decreased
Bacteroidetes/Firmicutes ratio, and an increased abundance of
potential proinflammatory Proteobacteria (Verdam et al., 2013).
The shifts in the intestinal microbiota populations were also
accompanied by increased levels of fecal calprotectin and plasma
C-reactive protein, which suggest that the intestinal microbiota
alterations found in obese humans are associated with local and
systemic inflammation and that the obesity-related microbiota
has a proinflammatory effect (Verdam et al., 2013). Finally,
Biagi and co-workers found that by evaluating the correlation
between systemic inflammation and the fecal microbiota that
about 9% of the variable microbiota was related to the increased
levels of pro-inflammatory cytokines IL-6 and IL-8 (Biagi
et al., 2010). All of the taxa that showed a slightly positive
correlation with either IL-6 or IL-8 belonged to the phylum
Proteobacteria (Biagi et al., 2010). The intestinal microbiota also
has many inflammation-suppressing fractions, which function
to; counteract some of the inflammatory bacteria, decrease
the inflammatory tone of the system, improve the barrier
function of the GI mucosa, and prevent inflammation-inducing
components from translocating into the body (Hakansson
and Molin, 2011). Furthermore, Clostridium cluster XIVa and
Faecalibacterium prausnitzii has been demonstrated to possess
anti-inflammatory effects by inhibiting NF-κB activation and IL-
8 secretion and stimulation of peripheral blood mononuclear
cells, which ultimately led to an IL-10/IL-12 ratio that favors anti-
inflammatory conditions (Sokol et al., 2008). By far, the most
studied inflammation-suppressing taxa of the GI microbiota
are from the genera of Lactobacillus and Bifidobacterium.
Lactobacillus and Bifidobacterium will be discussed further in the
probiotics section.
While the all of the direct mechanistic contributions of the
GI microbiota on systemic immunity beyond the intestinal
mucosa remain to be determined, these studies demonstrate that
commensal bacteria can impact host immunity beyond the GI
tract. Table 1 summarizes our current understanding of the effect
of the intestinal microbiota on systemic immunity.
Effects of the GI Microbiota on Pulmonary
Health
Priming of Intestinal and Lung Mucosal Immunity
It is important to understand the cross-talk and collaboration
between the GI tract and the respiratory tract at both an immune
and microbial level. Numerous studies have shown that fluids,
particles, or even microorganisms deposited into the nasal cavity
of mice can also be found in the GI tract a short time later
(Southam et al., 2002). In fact, as little as 2·5µl of inoculum into
the nasal cavity can later be detected in the GI tract (Southam
et al., 2002). Therefore, the GI tract will ultimately be exposed to
any pathogen or antigen that is introduced into the respiratory
system. This also suggests that the mucosal immune system of
the GI tract may serve as a primary sensor of foreign antigens
and organisms from the environment. Importantly, disturbances
in the intestinal homeostasis by either alterations in the host’s
genetics or alterations in the microflora could have drastic effects
on systemic (e.g., lung) immune responses (see Figure 2). We
have also provided a summary our current understanding of
the effect of the intestinal microbiota on pulmonary health in
Table 2.
Allergies and Asthma
Allergies are often associated with an abnormal Th2 T cell
response. Th2 cells are characterized by their ability to produce
IL-4, IL-5, IL-9, and IL-13 (McLoughlin and Mills, 2011).
The notion that the alterations of immune responses in the
gut can directly affect the development of allergic disease in
the lung is now widely accepted due to strong epidemiologic
(Björkstén et al., 2001) and experimental evidence (Noverr
et al., 2004, 2005; Maizels, 2009). A pivotal study reported by
Noverr et al. (2004) demonstrated that allergies can develop as
a consequence of an altered intestinal microbiota (Noverr et al.,
2004). Antibiotic treated mice were given a single oral dose of
Candida albicans. This significantly altered the composition of
the intestinal microbiota (Noverr et al., 2004). Treated animals
had more CD4 cell–mediated inflammation in the lung following
aerosol introduction of an allergen compared to mice with
a normal GI flora (Noverr et al., 2004). This suggests that
alterations in the GI flora can facilitate an immunological
state that is predisposed to respiratory allergies. There is a
growing interest in understanding other T cell subsets in the
development of allergy and asthma, specifically the role of
Th17 cells and Th9 cells, which may be impacted by GI
microbes (Forsythe, 2014). In addition, Vital and colleagues
examined the associations between the intestinal microbiota
and allergic airway disease in both young and old mice
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TABLE 1 | Current understanding of the effects of the intestinal microbiota on systemic immunity.
Microbial species or product Effects on systemic immunity
EFFECT OF THE INTESTINAL MICROBIOTA ON SYSTEMIC IMMUNITY
• Bacteroidesfragitis PSA+ strains • Higher levels of circulating CD4+T cells and Thl cells
• Clostridial cluster IV •Enhances anti-inflammatory signaling
• Expansion of lamina propria and systemic regulatory T cells
• Increases IL-10 secretion
• Bacteroides vulgatus •Influences T cell differentiation favoring a Th2 over a Thl phenotype
• Increases levels of IgE, IgGl, IL-4 and decreased IFN-γ
• Segmented Filamentous Bacteria • Induces expansion of the Thl7 cell population
• Slight increase in Thl cells
• Lachnospiraceae •Increased production of butyric acid
• Loss of Akkermansia, Ruminococcus, Pseudobutyrivibrio •Correlates with a decreased levels of RANKL
• RANKL is expressed by T helper cells and is involved in DC maturation.
• Parabacteroides distasonis (Membrane Fractions) •Decreased levels of proinflammatory cytokines
• Stabilization of the intestinal microbial ecology
• Lactobacillus spp. •Promote DC maturation and production of regulatory cytokines
• Expansion of CD4+ regulatory T cells
• Faecalibacterium •Inhibition of NF-κB activation through Butyrate production
• Interact with DCs promoting induction ofTregs
• Induce high amounts of IL-10 in antigen presenting cells
• May be able to block expansion of Thl7 cells
• Bacteroides thetaiotaomicron •Can increase gut permeability in mice deplete of microflora.
• Increases metabolites involved in gluconeogenesis (succinate)
• Firmicutes to Bacteroidetes Ratio •Affects development of Oral Tolerance
• Influences how the gut microbiota metabolized fiber
• Increased/decreased levels of SCFAs
• Increased/decreased levels of fecal calprotectin and plasma C-reactive protein
that were sensitized and challenged with house dust mite.
They found that the microbial community structure changed
with age and allergy development and interestingly that the
alterations in the intestinal microbiota from young to old mice
resembled the microbial structure of mice after house dust mite
challenge. The changes in the intestinal microbial communities
were also associated with increased levels of serum IL-17A.
Further, old mice developed a greater allergic airway response
compared to young mice. Vital and colleagues also suggest the
composition of the gut microbiota changes with pulmonary
allergy, indicating bidirectional gut-lung communications (Vital
et al., 2015).
Infectious Diseases
It is evident that the intestinal microbiota plays a crucial role
in the regulation and immune response to respiratory viral
infections such as influenza (Ichinohe et al., 2011). A recent
study from Ichinohe and co-workers demonstrated that the GI
microbiota directly influenced virus-specific CD4 and CD8 T cell
subsets in experimentally infected mice (Ichinohe et al., 2011).
Treatment of mice with different antibiotic regimens revealed
a population of neomycin-sensitive commensal organisms
associated with a protective immune response in the lung
following influenza infection. Furthermore, injection of TLR
ligands, either locally in the lung or at distal sites, rescued the
immune impairment in the antibiotic-treated mice. In addition,
an intact GI microbiota was required for expression of the
proinflammatory chemokines pro–IL-1β and pro–IL-18, which
are necessary for influenza clearance (Ichinohe et al., 2010). This
suggests that the intestinal microbiota provides microbial signals
or determinants that are critical for immune priming and shaping
the response to viral pneumonia.
Similar observations regarding the critical role of the intestinal
microbiota in the regulation and immune response to respiratory
bacterial infections have also been made (Fagundes et al., 2012).
Fagundes et al. (2012) employed germ-free mice to analyze the
ability of the host to resist bacterial infection. Germ-free mice
were highly susceptible to pulmonary infection with the bacterial
pathogen Klebsiella pneumonia. The enhanced susceptibility
to K. pneumoniae was associated with increased levels of
IL-10, which suppresses neutrophil recruitment, and permits
pathogen growth and dissemination. The administration of a
TLR agonist followed by LPS inoculation prevented pulmonary
K. pneumoniae infection, reduced IL-10 secretion, normalized
TNF-α and CXCL1 levels, and neutrophil mobilization to
the lungs (Fagundes et al., 2012). Germ-free mice that were
conventionalized (normal mouse intestinal flora has been
restored) had significantly less K. pneumoniae in the lungs
and blood (Fagundes et al., 2012). Conventionalization also
restored neutrophil influx, CXCL-1, TNF-α, and IL-10 to levels
found in wild-type mice (Fagundes et al., 2012). These findings
suggest that the commensal microbiota maintain host defenses to
infectious agents by facilitating a normal inflammatory response
to pulmonary pathogens.
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FIGURE 2 | Intestinal dysbiosis affects systemic immune responses. A model for the regulatory influence of the gastrointestinal microbiota on systemic immune
responses. Antigens are processed by GI tract dendritic cells (DC). The DC then promote the proliferation and expansion of various T cell subsets in response to
antigens. T cells then home to sites of infection or antigen exposure. Optimal inflammatory/non-inflammatory conditions and the production of various bacterial
metabolites are affected by the composition of the intestinal microbiota. Disruptions in the intestinal microbiota (dysbiosis) lead to impaired proliferation and expansion
of T cell subsets, increased inflammation, and loss or imbalance of bacterial metabolites, all of which can have a negative impact on health and systemic immune
response.
Gut-derived Sepsis and Acute Respiratory
Distress Syndrome
Gut-derived sepsis is the process during which gut-derived
proinflammatory microbial and non-microbial factors induce or
enhance a systemic inflammatory response syndrome (SIRS),
acute respiratory distress syndrome (ARDS), or multiple organ
dysfunction syndrome (MODS). Several mechanistic theories
of gut-derived sepsis leading to SIRS, ARDS, or MODS, have
been postulated (Deitch, 2002, 2012; Senthil et al., 2006; Clark
and Coopersmith, 2007; Deitch and Ulloa, 2010). The “gut-
lymph” theory proposes that macrophages and other immune
cells in the intestinal submucosa or the mesenteric lymph
nodes are sufficient to contain the majority of translocating
bacteria. However, any surviving bacteria, cell wall fragments, or
protein components of the dead bacteria that escape macrophage
containment together with cytokines and chemokines produced
in the gut, travel along the mesenteric lymphatics to the cisterna
chyli. These products then enter into the systemic circulation
through the left subclavian vein, via the thoracic duct. Access
to the pulmonary circulation leads to uncontrolled activation
of alveolar macrophages leading to acute lung injury or ARDS
and then MODS (Senthil et al., 2006). Several experimental
models support this theory. For example, experimental models
of endotoxinemia (Watkins et al., 2008) trauma-hemorrhagic
shock (Senthil et al., 2007) or burn injury (Lee et al., 2008)
all support this theory. An additional theory put forward by
Clark and Coopersmith is the “intestinal crosstalk” theory (Clark
and Coopersmith, 2007). This theory assumes a three-way
partnership among the intestinal epithelium, immune tissues,
and the endogenous microflora of the gut. Within this three
dimensional relationship, each factormodifies the others through
crosstalk. During normal homeostasis all three components
interact normally, which facilitates intestinal crosstalk with extra-
intestinal tissues. However, in critically ill patients, loss of the
balance between these highly interrelated systems results in the
development of systemic manifestations of disease, specifically
SIRS, ARDS, or MODS (Clark and Coopersmith, 2007). The
mechanisms governing gut-derived sepsis and ARDS are poorly
understood and are actively being investigated.
Chronic Obstructive Pulmonary Disease
COPD is an inflammatory disorder characterized by incomplete
reversible airflow obstruction leading to increased mortality and
morbidity (Keely et al., 2012; Hui et al., 2013). It has been known
for several years that individuals who suffer from COPD have an
altered lung microbiome compared to healthy individuals. (Keely
et al., 2012; Hui et al., 2013). There is evidence that components
of the gastrointestinal microflora, specifically Gram negative
bacilli, may also make up a component of the lung microflora
and may be increased in individuals with COPD (Keely et al.,
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TABLE 2 | Current understanding of the effects of the intestinal microbiota on pulmonary immunity.
Pulmonary diseases Changes to the intestinal microbiota
EFFECT OF THE INTESTINAL MICROBIOTA ON PULMONARY HEALTH
• Allergies and Asthma • Antibiotic-depleted intestinal flora
• Significantly moreCD4Tcell-mediated inflammation in responsetoan allergen
•Immunological state that is predisposed to toward respiratory allergies
• Infectious Disease • Antibiotic-depleted intestinal flora
• Impaired levels of virus-specific CD4 and CD8Tcell subsets
• Treatment with TLR ligands (lung or Intestine) rescued the immune impairment
• The normal Gl microbiota is required for expression of pro-IL-lβ and pro-IL-18
• Germ-free mice
• Increased susceptibly to pulmonary infection with bacterial pathogens
• Increased levels of IL-10 during infection
• Suppressed neutrophil recruitment
• Increased pathogen growth and dissemination
• Treatment with TLR agonist followed restored normal immune responses to bacterial infection
• Conventionalized Germ-free mice exhibit normal immune responses to bacterial infection
• Gut-derived sepsis and ARDS • The “gut-lymph” theory
• Macrophages and other immune cells in the intestinal kill the majority of translocating bacteria
• Surviving bacteria, cell wall fragments, or protein components may reach the lungs
• Increased activation of alveolar macrophages leading to acute lung injury
• The “intestinal crosstalk” theory
• A three-way partnership amongthe intestinal epithelium, immune tissues, and microflora of the gut
• Each factor modifies the others through crosstalk
• Normal homeostasis all three components interact normally
• Critically ill patients exhibit a loss of the balance between these systems
• COPD • Cigarette smoke is known to selectively inhibit bacterial growth
• Favors a Gram negative bacilli population
2012; Hui et al., 2013). These bacteria are resistant to cigarette
smoke and may contribute to severe exacerbations of COPD
(Keely et al., 2012; Hui et al., 2013).While no definitive studies on
the effect of smoking on the respiratory or intestinal microbiome
have been performed, it is possible that smoke-induced changes
to the intestinal microbiome may exacerbate COPD symptoms
(Keely et al., 2012; Hui et al., 2013).
Potential Mechanisms of GI Mediated Lung
Immunity
The mechanisms by which the intestinal microbiota exert a
systemic immunomodulatory effect are not fully understood,
but several potential pathways may be involved. Highlighted
below are several potential mechanisms regulating gut-mediated
systemic immunity. Figure 3 provides a conceptual figure of our
current understanding to the potential mechanisms involved in
the immune regulation along the gut-lung axis.
Toll Like Receptor (TLR) Activation
The intestinal immune system initiates immune signaling
events via the interactions of the gut microbiota with pattern
recognition receptors of the innate immune system (i.e., TLRs).
TLRs recognize microbial components and trigger inflammatory
responses (Abreu, 2010). Different bacterial products, such
as lipopolysaccharide, lipoteichoic acid, CpG, peptidoglycan,
and polyinosinic:polycytidylic acid, stimulate TLR signaling
(Abreu, 2010). One downstream effect of TLR signaling is the
activation of the transcription factor NF-κB, which is required
for expression of many genes regulating innate immunity
and inflammation (Abreu, 2010). The intestinal microbiota is
crucial for maintaining normal TLR signaling (Round et al.,
2011; Fagundes et al., 2012). Microbiota-mediated activation
of antigen-specific CD4 and CD8 T cells, pathogen specific-
antibodies, steady state expression of mRNA for pro–IL-1β and
pro–IL-18, inflammasome activation, and migration of dendritic
cells (DCs) from the tissue to the draining lymph node, which
leads to normal T cell priming, all occur in a TLR dependent
manner (Ichinohe et al., 2010). Further, intestinal initiated TLR
signaling has been shown to induce lung immune responses by
Ichinohe and colleagues, who showed that a single dose of LPS
delivered intrarectally, restored an immune response in the lung
of influenza infected mice (Ichinohe et al., 2010). The elucidation
of the major bacterial species or bacterial products necessary to
maintain normal microbiota-TLR signaling is an area primed for
investigation.
T and B Cell Homing
Tissue specific homing of lymphocytes is crucial for an
effective immune response and clearance of infection. The
localization and homing of lymphocytes is determined by
expression of integrin and chemokine receptors, such as CC-
chemokine receptor 9 (CCR9) (Christensen et al., 2002; Niess and
Reinecker, 2005; Meijerink and Wells, 2010). Specific adhesion
and chemokine receptors expressed by lymphocytes allow these
immune cells to target tissues that express their cognate ligands
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FIGURE 3 | Conceptual figure of the gut-lung axis. Proposed model for the regulatory influence of the gastrointestinal microbiota on the immunology of the lung.
Microbes in the intestine are sampled by DCs either directly from the lumen or following translocation throughM cells to the GALT. A combination of signals from the
microbes results in phenotypic changes in the DCs and migration to the draining lymph node. DCs promote the activation of various T cell subsets within the MLN and
the production of various regulatory cytokines such as IL-10, TGF-β, INFγ, and IL-6. T cell subsets then acquire immune homing molecules (i.e., CCR9, CCR4, and
CCR9). Following immune challenge in the airway, cells activated in the GALT and MLN traffic to the respiratory mucosa via CCR4 or CCR6 where they promote
protective and anti-inflammatory responses. In addition, bacterial derived products such as LPS can bind to TLR present on both intestinal epithelial cells and
macrophages, leading to the production of various cytokines and chemokines. TLR activation also includes the expression of NF-kB in macrophages. Production of
various bacterial metabolites (e.g., SCFAs) also affect the gut-lung axis, as these products are transported to the lung, where they can alter the levels of inflammation.
and home to areas of high chemokine secretion (Christensen
et al., 2002). T cells acquire the capacity to home to non-lymphoid
tissues by direct interaction with mucosal DCs at the sites of
antigen acquisition. DC-mediated imprinting of T cells confers
selectivity for specific non-lymphoid tissues, such as the gut,
skin, and lung (Sigmundsdottir and Butcher, 2008; Hart et al.,
2010; Mikhak et al., 2013). Dendritic cells sense antigen in tissues
before migrating to draining lymph nodes, where they have the
ability to activate and influence the differentiation of naïve T cells.
Gut DCs promote the expression of α4β7 and CCR9 on T cells,
and, in doing so, enable T cells to migrate to the small intestine
by homing to the intestinal ligand MAdCAM-1 and chemokine
CCL25 (Sigmundsdottir and Butcher, 2008). Alternatively, lung
DCs promote the expression of CCR4 on T cells, which allows
for activated T cells to traffic into the lung via increased levels of
CCL17 (Mikhak et al., 2013).
The ability to induce tissue-specific homing of lymphocytes
suggests that mucosal surfaces can not only induce homing back
to the site of antigen acquisition but may be able to target distal
mucosal sites as well via altered lymphocyte priming. In support
of this, Ruane et al. (2013), found that lung DCs can specifically
up-regulate the expression of the gut-homing integrin α4β7 on T
cells, which guidedmigration to the GI tract. Consistent with this,
intranasal immunization with Salmonella induced protective
immunity against enteric challenge with Salmonella and was
dependent on lung DCs (Ruane et al., 2013).
Additional mechanisms allow for lymphocytes to traffic to
multiple mucosal sites to combat infection at mucosal surfaces.
For example, CCR6 is expressed on immature DCs, most B cells,
subsets of CD4+ and CD8+T cells, andNatural Killer T cells (Ito
et al., 2011). The cognate ligand of CCR6, CCL20, is expressed
by a variety of epithelial cell types including keratinocytes,
pulmonary epithelial cells, and intestinal epithelial cells (Ito et al.,
2011). The expression of CCL20 in these tissues remains at a low
steady-state level, but is strongly induced by pro-inflammatory
signals and TLR agonists originating from bacterial species
(Ito et al., 2011). These data suggest that pathogens/antigens
encountered in the gut or the lung can prime central and
effector memory T cells, which then home to sites of new
infection (i.e., sites of inflammation). Thus, CCR6 may be critical
for an effective immune response within the gut-pulmonary
axis.
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Targeting the Intestinal Microbiota in the
Prevention of Lung Related Infectious
Diseases
Prevention of Respiratory Infections with
Probiotics
The use of probiotics for the treatment of various diseases and
for the maintenance of health in general has become an intensely
studied area, with broad appeal. Probiotics are now used to
treat a variety of aliments including diarrhea, gas, cramping,
vaginal yeast infections, urinary tract infections, and to help
control inflammatory bowel disease (IBD). Studies are also
underway evaluating the benefits of probiotics in the treatment
of colon cancer, skin infections, irritable bowel syndrome (IBS),
liver disease, rhinoconjunctivitis/rhinosinusitis, and lung health
(Forsythe, 2011; Eslamparast et al., 2013; Kumar et al., 2013;
Baquerizo Nole et al., 2014; Kramer andHeath, 2014; Sandhu and
Paul, 2014). Table 3 describes the current research targeting the
intestinal microbiota for the prevention of lung related infectious
diseases.
The benefits of probiotics in the maintenance and regulation
of lung health has been described in several studies (Forsythe,
2011, 2014; Yoda et al., 2012; West, 2014). One of the first
studies indicating that intestinal microflora may influence lung
health came from the study of obese mice. Researchers found
that in obese mice the GI microbiota plays an important role in
controlling inflammation in the lungs (Yoda et al., 2012). Mice
fed heat-killed Lactobacillus gasseri had significant increases in
pulmonary mRNA expression of cytokines and other immune
molecules accompanying the changes in their GI bacterial
profiles (Yoda et al., 2012). These results suggest that Lactobacilli
may stimulate the respiratory immune responses of mice to
enhance host defenses against respiratory infection by increasing
inflammatory signaling.
Additionally, the probiotic bacteria Lactobacillus rhamnosus
displays immune stimulatory effects associated with increased
resistance to infection (Salva et al., 2010). L. rhamnosus feeding
not only attenuated infection with Salmonella Typhimurium, an
intestinal pathogen, but also conferred resistance to infection
with Streptococcus pneumoniae, a respiratory pathogen. Probiotic
treatment decreased the burden of S. pneumoniae in the lung,
prevented dissemination to the blood, and increased INFγ, IL-6,
IL-4, and IL-10 in bronchoalveolar lavage (BAL) fluid (Salva et al.,
2010). Interestingly, while both of the tested L. rhamnosus strains
improved resistance to intestinal S. Typhimurium, only one
strain provided a beneficial protective effect against pulmonary
infection with S. pneumoniae (Salva et al., 2010). This suggests
differential probiotic effects and that different infectious diseases
may benefit from a specific and unique probiotic treatment
regime.
Furthermore, Alvarez et al. (2001) found that mice
administrated Lactobacillus casei prior to pulmonary challenge
with Pseudomonas aeruginosa exhibited increased pathogen
clearance, phagocytic activity of alveolar macrophages, and
IgA in BAL (Alvarez et al., 2001). Similarly, Hori et al. (2001)
observed parallel results in murine viral infection models.
Feeding mice L. casei for 4 months prior to challenge reduced
influenza viral titers in nasal washings, which was accompanied
by a significant increase in natural killer (NK) activity and IFNγ
and TNF-α production (Hori et al., 2001).
Prevention of Respiratory Infections with Oral
Vaccines
Over the past two centuries the study and use of vaccines
has become increasingly sophisticated. However, even with
technological advances many infectious diseases have thwarted
the development of effective vaccines. While many routes of
vaccination exist, one emerging area of vaccinology is mucosal
immunization. This approach provides several benefits over
TABLE 3 | The current research targeting the intestinal microbiota for the prevention of lung related infectious diseases.
Microbial species or product Effects on pulmonary health
CURRENT METHODS FOR TARGETING THE INTESTINAL MICROBIAL FOR TREATMENT OF RESPIRATORY DISEASES
• Probiotics (Commonly used probiotics)
• Lactobacillus gasseri
• Lactobacillus rhamnosus
• Lactobacillus casei
• Lactobacillus acidophilus
• Bifidobacterium lactis
• Lactobacillus delbruckii subsp. Bulgaricus
• Streptococcus thermophiles
• Bifidobacterium bifidum
• Bifidobacterium breve
• Enhanced phagocytosis level during normal conditions
• Suppressed levels of phagocytosis during allergic conditions
• Enhance the production of antigen-specific IgG and IgAantibodies
• Suppressed the proliferation of mononuclear cells during inflammation
• Reduced burden of pathogens in the lung
• Prevents dissemination to the blood
• Increased INFγ,IL-6, IL-4,TNF-α and IL-10 levels in BAL
• Increased natural killer cell activity
• Oral vaccines against Respiratory Pathogens
• Mycobacterium spp.
• Francisella tularensis
• Brucella melitensis
• Mycobacterium tuberculosis
• Increased levels of serum antibodies
• Increased production of IL-2 and INFγ from splenocytes
• Increased levels of antigen-specific antibodies in BAL fluid
• Enhanced proliferation of antigen-specific INFγ producing cells
• Significant reduction in pathogen burden in the lung following infection
• Probiotic coupled vaccines (Probiotics commonly used as adjuvants)
• Lactococcus lactis
• Lactobacillus rhamnosus
• Bifidobacterium animalis
• Lactobacillus paracasei
• Increased antigen-specific IgM, IgG (IgGl and lgG2), and IgAantibodies
• Serum, BAL, and intestinal lavage fluids.
• Stimulation of both Thl and Th2 responses
• Increased production of both INFγ and IL-4.
• Induces a cross-protective immunity to multiple serotypes
• Can be enhanced by a prime-boostvaccination strategy
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conventional systemic vaccination, including higher levels of
antibodies and protection at the mucosal surface. In addition,
mucosal vaccines can target specific mucosal surfaces such as
the respiratory, genital, or intestinal mucosa. Noteworthy is that
vaccination at one mucosal surface often confers resistance at
other sites (Ryan et al., 2001; Pasetti et al., 2011). Thus, it is
possible to immunize against respiratory pathogens using a gut
vaccination strategy.
Several studies have addressed the potential of gut-mediated
lung immunity (Doherty et al., 2002; Izadjoo et al., 2004;
Aldwell et al., 2006; KuoLee et al., 2007). For example,
Doherty et al. (2002) sought to protect the lung against
infection with Mycobacterium tuberculosis by targeting the gut
mucosa. Comparing subcutaneous immunization of mice with
oral immunization using a subunit vaccine carrying two M.
tuberculosis immunodominant proteins, they found that oral
vaccination was relatively less effective. However, by using a
heterologous priming and boosting strategy, oral immunization
induced significant systemic type 1 responses, which were
comparable to, or better than, those obtained following standard
subcutaneous immunization protocols. Moreover, the immune
responses correlated with protection against subsequent aerosol
infection with virulent M. tuberculosis similar to or greater than
that obtained by repeated subcutaneous vaccinations (Doherty
et al., 2002).
Evaluating the ability of orally administered live attenuated
Brucella melitensis to elicit cellular and humoral immune
responses and to protect mice against intranasal challenge with
virulent B. melitensis, Izadjoo and colleges found increases
in serum antibodies directed against lipopolysaccharide and
non-O-polysaccharide antigens. Additionally, orally delivered
B. melitensis elicited a systemic response as characterized by
increased production of IL-2 and IFNγ from splenocytes. Oral
immunization of mice with live attenuated B. melitensis protected
against disseminated infection and enhanced clearance of the
challenge inoculum from the lungs. Optimal protection following
inoculation with live bacteria was dose dependent and enhanced
by a booster vaccine inoculation. These data suggest that oral
immunization may provide protection from pneumonia due to
Brucella (Izadjoo et al., 2004).
Two additional studies utilizing oral vaccination
demonstrated protective immune responses against
Mycobacterium spp. and Francisella tularensis (Aldwell
et al., 2006; KuoLee et al., 2007). Both studies showed an
induction of antigen-specific antibody responses in the serum
and bronchoalveolar lavage fluids, proliferation of antigen-
specific IFN-γ producing cells, and an overall reduction in
pathogen burden in the lung (Aldwell et al., 2006; KuoLee et al.,
2007). These studies demonstrate the potential of GI mucosal
vaccination to prevent lung infections. Furthermore, these
data suggest that oral vaccination may represent an attractive
alternative strategy for the prevention of infection with these two
pathogens.
Prevention of Respiratory Infections with
Probiotic Coupled Vaccines
Preclinical data suggests that vaccine responses may be improved
by modulation of the gut microbiota. Several animal studies
and human clinical trials have been performed. Mice orally
immunized with a recombinant Lactococcus lactis modified
to express the pneumococcal protective protein A (PppA) in
the cell wall were protected from subsequent lung infection
with Streptococcus pneumoniae. Oral immunization with L.
lactis expressing PppA increased anti-PppA IgM, IgG, and IgA
antibodies in serum, in bronchoalveolar, and in intestinal lavage
fluids. A mixture of Th1 and Th2 responses were observed,
characterized by the presence of both IgG1 and IgG2a anti-PppA
antibodies in serum and BAL and by the production of both IFNγ
and IL-4. Furthermore, oral immunization was enhanced by a
prime-boost strategy, which induced cross-protective immunity
to all S. pneumoniae serotypes tested (Villena et al., 2008).
Another animal study evaluated a recombinant oral L. lactis
vaccine against the influenza H5N1 strain. Immunization with
L. lactis expressing the H5N1 HA antigen induced HA-specific
serum IgG and fecal IgA antibody production and mice were
completely protected against a lethal challenge of the H5N1 virus
(Lei et al., 2010).
Several human clinical trials have been completed in this
area. Highlighted below are probiotic-coupled respiratory
vaccine human clinical trials. Lactobacillus rhamnosus GG
pretreatment for 28 days enhanced seroprotection against
H3N2 influenza following nasal vaccination with the trivalent
live attenuated influenza vaccine containing H1N1-like,
H3N2-like, and B-like strains. However, no improvement
in protection against the H1N1 and B strains was observed
at 28 days and no seroprotection was found at 56 days
for any strain (Davidson et al., 2011). An additional study
examined the effects of 6 wks. of daily Bifidobacterium animalis
and Lactobacillus paracasei probiotics administration as an
immune primer prior to intramuscular influenza vaccination
containing H1N1-like, H3N1-like, and B strains. Individuals
given probiotic-coupled vaccination had significantly higher
vaccine-specific IgG (IgG1 and IgG3), as well as, significantly
higher salivary IgA (Rizzardini et al., 2012). However, another
study reported no significant difference between the probiotics
and placebo groups when evaluating innate immune response
to infection (Akatsu et al., 2013). Taken together animal
studies and human clinical trial data suggest that coupling
vaccines with probiotics may increase the effectiveness of
vaccines. However, the data are conflicting. It is clear that
optimization of the dosing strategy, as well as, the type of
probiotic used will be critical to achieve maximal vaccine
effectiveness.
Conclusions
While we are now beginning to understand the effect of the
GI microbiota on lung immunity, characterization of the lung
microbiota may also provide valuable insight into lung-mediated
immune regulation in response to influenza and pneumonia, as
well as, cystic fibrosis, COPD, allergies, and asthma. This review
has focused on the mechanisms that govern the effects of the
GI microbiota on immune effector and regulatory functions.
While there have been significant advancements made in the
past 10 years in our understanding of the global impacts of
the GI microbiota on human immune function, many questions
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TABLE 4 | Current understanding of the GI microbiota and future questions.
What is known What is unknown
THE INTESTINAL MICROBIOTA AND HOST IMMUNITY
• The intestinal mucosa is an immune-privileged site • What is the precise composition of a healthy microbiota required for maximum
immune-mediated protection?
• The intestinal microbiota plays an integral part in the development of
the immune system
• Peyer’s patches
• CD8αβ intraepithelial lymphocytes
• Isolated lymphoid follicles
• Mucosal IgA
• Vascularization
• How can we to establish and maintain a healthy microbiota throughout life?
• The intestinal flora is required for normal expansion of T cell subsets
and induction of anti-inflammatory cytokines
• T regulatory cells
• Thl7 cells
• Thl v. Th2 responses
• What are the direct mechanisms by which gut acquired immunity is translated to
protective systemic immunity?
• The Gl microbiota directly participates in protection against allergic,
autoimmune, and infectious diseases
• To what extent does the immune system influence other microbiomes [i.e., lung, skin, or
urogenital tract)?
• Commensal species of bacteria or bacterial derived products can be
used as novel therapeutics forthe treatment of diseases
• Is immune dysfunction a cause or consequence of alterations in the Gl microbiome
associated with disease?
• The intestinal microbiota is important for normal systemic immune
response
• Where do the microbial signals regulate immune function and immune function
regulating microbial composition operate?
• Immune responses generated in the intestinal mucosa are often
protective at distal mucosal sites
• How are regulatory cells that develop in the gut directly targeted to distal sites such as,
the skin orthe lung?
• How do we manipulate an unhealthy microbiota to reestablish its positive effects on
health?
• Can we targetthe gut-lung axis forthe treatment of respiratory illness?
still remain. Table 4 describes our current understanding of GI
regulation of the immune system and areas that remain to be
explored.
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1990, to January, 2015, by use of the terms “Gut-Lung Axis,”
“microbiota,” “microbiome,” “oral vaccines,” “oral vaccines +
microbiota,” and “microbiota + respiratory infection.” Articles
resulting from these searches and relevant references cited in
those articles were reviewed. Articles published in English were
included.
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